Hispidulin attenuates the social withdrawal in isolated disrupted‐in‐schizophrenia‐1 mutant and chronic phencyclidine‐treated mice
Open Access
- 4 March 2020
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 177 (14) , 3210-3224
Abstract
Background and Purpose: Hispidulin is a flavonoid isolated from Clerodendrum inerme that was found to inhibit intractable motor tics. Previously, we found that hispidulin attenuates hyperlocomotion and the disrupted prepulse inhibition induced by methamphetamine and N‐methyl‐d‐aspartate (NMDA) receptor antagonists, two phenotypes of schizophrenia resembling positive symptoms. Hispidulin can inhibit COMT, a dopamine‐metabolizing enzyme in the prefrontal cortex (PFC) that is important for social interaction. Here, we investigated whether hispidulin would affect social withdrawal, one of the negative symptoms of schizophrenia.Experimental Approach: We examined whether acute administration of hispidulin would attenuate social withdrawal in two mice models, juvenile isolated disrupted‐in‐schizophrenia‐1 mutant (mutDISC1) mice and chronic phencyclidine (PCP)‐treated naïve mice.Key Results: In chronic PCP‐treated mice, hispidulin (10 mg·kg−1, i.p.) attenuated social withdrawal similar to that observed with dopamine D1 receptor antagonist (SCH‐23390, 0.02 mg·kg−1, i.p.) and was mimicked by the selective COMT inhibitor, OR‐486 (10 mg·kg−1, i.p.). Hispidulin increased extracellular dopamine levels in the PFC of chronic PCP‐treated mice. In isolated mutDISC1 mice, hispidulin also reversed social withdrawal. In both models, intra‐PFC microinjection of a D1 agonist (SKF‐81297: 10 nmol/mouse/bilateral) reversed the impairment of Ser897phosphorylation at the GluN1 subunit of NMDA receptors, suggesting the association between GluN1 Ser897‐phosphorylation and D1 activation in the PFC exits in both models.Conclusions and Implications: Hispidulin attenuated social withdrawal by activating D1 receptors indirectly through elevated dopamine levels in the PFC by COMT inhibition. This nature of hispidulin suggests that it a potential novel therapeutic candidate for the treatment of negative symptoms in schizophrenia.Keywords
Funding Information
- Ministry of Science and Technology, Taiwan (MOST108‐2325‐B002‐029‐MY3, MOST108‐2321‐B002‐005, MOST104‐2923‐B002‐006‐MY3, MOST104‐2325‐B002‐010, MOST103‐2325‐B002‐037, NSC102‐2325‐B002‐047, NSC101‐2325‐B002‐048, NSC100‐2325‐B002‐050)
- Smoking Research Foundation
- Nakatomi Foundation
- Takeda Science Foundation
- Japan Society for the Promotion of Science (26460240, 15K08218, 16K10195, 17H04252)
This publication has 63 references indexed in Scilit:
- Adolescent Stress–Induced Epigenetic Control of Dopaminergic Neurons via GlucocorticoidsScience, 2013
- Clerodendrum inermeLeaf Extract Alleviates Animal Behaviors, Hyperlocomotion, and Prepulse Inhibition Disruptions, Mimicking Tourette Syndrome and SchizophreniaEvidence-Based Complementary and Alternative Medicine, 2012
- Animal research: Reporting in vivo experiments: The ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Knockdown of DISC1 by In Utero Gene Transfer Disturbs Postnatal Dopaminergic Maturation in the Frontal Cortex and Leads to Adult Behavioral DeficitsNeuron, 2010
- Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophreniaTrials, 2009
- Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humansProceedings of the National Academy of Sciences, 2007
- Hypofunctional glutamatergic neurotransmission in the prefrontal cortex is involved in the emotional deficit induced by repeated treatment with phencyclidine in mice: Implications for abnormalities of glutamate release and NMDA–CaMKII signalingBehavioural Brain Research, 2007
- The Functional Significance of Social Cognition in Schizophrenia: A ReviewSchizophrenia Bulletin, 2006
- Neurotransmitter aberrations in schizophrenia: New perspectives and therapeutic implicationsLife Sciences, 1997
- Differential effects of phencyclidine (PCP) and ketamine on mesocortical and mesostriatal dopamine releaseLife Sciences, 1989